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Abstract 
In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-
dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates 
sphingosine-1-phosphate (S1P) which can be released from the cell and activates S1P 
receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised 
triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating 
changes in blood pressure has never been studied. Therefore, we assessed this in the current 
study. 
The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control 
C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also 
known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or 
an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in 
isolated mouse aortic rings. 
The hypotensive response to anandamide was significantly attenuated by BML-258 but not 
by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic 
but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in 
denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact 
rings. 
This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid 
hypotension induced by anandamide. Generation of S1P in response to anandamide likely 
activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These 
findings have important implications in our understanding of the hypotensive and 
cardiovascular actions of cannabinoids. 
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1. Introduction 
In a previous study (Mair et al., 2010), we identified a novel pathway which may underlie the 
endothelium-dependent vasodilator effects of anandamide in the rat coronary artery. This 
pathway involves the activation of sphingosine kinase 1 (SK1), the enzyme that catalyses the 
phosphorylation of sphingosine to produce sphingosine-1-phosphate (S1P), release of S1P 
and activation of S1P receptors on the vascular endothelium. Thus we proposed that this 
pathway allows S1P to access local populations of S1P receptors (Mair et al., 2010). Since 
anandamide has well-documented effects on blood pressure (BP), we sought to investigate if 
SK is required for anandamide to induce hypotension in anaesthetised mice and if S1P 
receptors are involved. 
Anandamide (AEA) is an endogenously-generated cannabinoid which activates the 
endocannabinoid receptors CB1 and CB2 and the vanilloid transient receptor potential 
channels of V1 type (TRPV1) receptor (Stanley et al., 2014). These endocannabinoids might 
also activate as yet uncharacterised receptors within the cardiovascular system, such as the 
orphan G protein-coupled receptors (GPCRs), GPR55 (Ryberg et al., 2007; Johns et al., 
2007) and GPR119 (Overton et al., 2006). Both GPR55 and GPR119 have been demonstrated 
to bind endocannabinoids and evidence also exists for a non-CB1/non-CB2 endothelial 
receptor, CBx (Offertaler et al., 2003; Zakrzeska et al., 2010) although this is controversial 
and requires further investigation. Both CB1 and CB2 receptors are located within the 
cardiovascular system (Batkai et al., 2004) and CB2 receptors are also present on circulating 
immune cells (Munro et al., 1993). The cardiovascular actions of endocannabinoids are 
complex and vary not only between species but also with experimental conditions (Randall et 
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al., 2004). In anaesthetised animals, intravenous (i.v.) administration of AEA evokes a 
triphasic response (Lake et al., 1997; Malinowska et al., 2001; Pacher et al., 2004). The initial 
phase I is characterised by a rapid and transient drop in BP which is accompanied by 
bradycardia, increased total peripheral resistance (TPR) and reduced cardiac contractility. 
Phase II consists of a short pressor response, marked by an increase in BP, cardiac 
contractility and mesenteric blood flow. This is followed by a more prolonged (~10 min) 
hypotension, a reduction in mesenteric blood flow, cardiac contractility and heart rate (HR) 
(Malinowska et al., 2012). The hypotensive phase I response is thought to involve a vagal-
mediated Bezold-Jarisch reflex and the activation of TRPV1 (Malinowska et al., 2001; 
Pacher et al., 2004). TRPV1 is expressed widely in the cardiovascular system, including on 
blood vessels (Zhang et al 2015; Fernandes et al 2012) and so AEA, or mechanisms 
downstream could affect blood vessels as well as the heart during phase I. However, to date 
no study has addressed whether the sphingolipid pathway is involved in mediating the phase I 
hypotensive response to AEA. Based on our in vitro data in the rat coronary artery (Mair et 
al., 2010), we hypothesised that generation of S1P in response to i.v. administration of AEA 
may underlie the phase I hypotensive response in the mouse. 
S1P is a lysophospholipid derived from phosphorylation of sphingosine. S1P can function 
inside cells to bind to target proteins such as histone deacetylase 1/2 (reviewed in Pyne et al. 
(2011)). Extracellular S1P can also bind to high affinity GPCRs (S1P1-5), of which S1P1, S1P2 
and S1P3 are localised within the cardiovascular system (Pyne et al., 2011). S1P mainly 
functions as a pro-survival signalling molecule while sphingosine is associated with pro-
apoptotic pathways and is an important regulator of cell stress responses (Hannun et al., 
2002). SK catalyses the formation of S1P from sphingosine and hence represents a key 
checkpoint in the regulation of the relative levels of sphingosine and its precursor, ceramide, 
and S1P; termed the sphingolipid rheostat. Two distinct SK isoforms have been identified 
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called SK1 and SK2 (Kohama et al., 1998; Liu et al., 2000). The two isoforms differ 
substantially in their tissue expression, substrate and inhibitor specificity, kinetic properties 
as well as their cellular localisation (Chan et al., 2013). SK1 is predominately localised in the 
cytoplasm of cells (Kohama et al., 1998; Olivera et al., 1998). In response to agonist-
stimulation, SK1 is phosphorylated, activated several-fold and translocated to the plasma 
membrane (Pitson et al., 2003). In contrast, phosphorylation of a nuclear export sequence in 
SK2 promotes its export from the nucleus (Ding et al., 2007). 
 
SK/S1P has been implicated in negatively regulating BP in hypertension (Spijkers et al., 
2012) and growing evidence suggests a link between the sphingolipid and endocannabinoid 
signalling systems. Phylogenetic analysis has identified a ~20% sequence homology between 
S1P and CB receptors and CB1 activation was shown to activate enzymes involved in 
sphingolipid metabolism (Galve-Roperh et al., 2000; Gustafsson et al., 2009). Furthermore, 
we (Mair et al., 2010) and others have presented evidence to suggest that S1P can act as an 
agonist at CB receptors and that the vascular effects of AEA require SK1 (Paugh et al., 
2006). Therefore, the aim of this study was to identify the contribution of the two SK 
isoforms to the phase I hypotensive action of AEA in vivo. We also examined whether S1P 
released from cells as a consequence of the activation of SK uses S1P receptors to induce this 
hypotensive response. 
 
2. Materials and Methods 
2.1 In vivo experiments 
All animal care and experimental procedures were in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and data are reported according to the ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) guidelines. Ethical approval was granted by the 
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University Ethics Committee and conformed to institutional regulations at the University of 
Glasgow. All mice used in the study were bred in the University of Glasgow, kept on a 12 
hour light/dark cycle and fed ad libitum.  
 
2.2 Administration of drugs 
Twenty four hours prior to BP measurements, animals were randomly assigned to receive one 
of the following treatments via intraperitoneal (i.p.) injection: 75 mg/kg of the dual SK1/2 
inhibitor, 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKi, Calbiochem, San Diego, 
CA, U.S.A. (French et al., 2003)); 75 mg/kg of the selective SK1 inhibitor, (2R,3S,4E)-N-
methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol (BML-258 (also known as SK1-I), 
Tocris Bioscience, Bristol, U.K. (Paugh et al., 2008)); 75 mg/kg of the selective SK2 
inhibitor, (R)-FTY720 methyl ether (ROMe) (Lim et al., 2011) or the equivalent volume of 
vehicle (0.1 ml of dimethyl sulphoxide (DMSO)). To test the effect of blocking S1P1 on the 
hypotensive response to anandamide, we employed 10 mg/kg of the selective antagonist, (R)-
3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid trifluoroacetate (W146, Avanti 
Polar Lipids, Alabaster, U.S.A. (Tarrason et al., 2011)), which was injected 30 min prior to 
BP measurement. Control animals received an equivalent volume of solvent (0.1 ml DMSO). 
All doses of drugs used were based on previously published studies. 
 
2.3 BP recording 
Haemodynamic measurements were performed under inhalational anaesthesia. Male 
C57BL/6 mice (mean weight 24 ± 3.5 g) were induced using 3% isoflurane supplemented 
with oxygen and maintained on 1.5% isoflurane in oxygen throughout the procedure. The left 
carotid artery was exposed and cannulated with a heparinised saline-containing cannula 
(Harvard Apparatus, Kent, U.K.) connected to a Bio-Pac Student Lab Pro pressure transducer 
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and recorder (BioPac Systems, Norfolk, U.K.). The right jugular vein was cannulated for 
administration of AEA (1 or 10 mg/kg in tocrisolve), methanandamide (1 or 10 mg/kg in 
tocrisolve) or the equivalent volume of tocrisolve (0.1 ml per injection). In all animals, BP 
was recorded continuously and 5 min was allowed between injections of AEA, 
methanandamide or vehicle at which time BP had stabilised. All injections were given rapidly 
over 1-2 s. 
 
2.4 Wire myography 
After mice (mean weight 33 ± 1.8 g) were killed with a rising concentration of CO2, the aorta 
was removed and transferred to oxygenated modified Krebs-Henseleit (KH) solution 
containing (in mM): 118 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1 MgSO4, 2.5 CaCl2, 11 
glucose. The aorta was used in these experiments as, although it is not a resistance vessel, the 
functional responses and S1P receptor populations have recently been reported (Roviezzo et 
al 2014). The aorta was carefully dissected to remove surrounding connective tissue and, in 
some experiments, the lumen was rubbed gently to remove endothelium and mounted in a 
wire myograph containing KH solution at 37 ˚C and aerated with 95% O2/5% CO2. After a 
period of equilibration, the vessels were placed under an optimum resting tension of 1 g for at 
least 30 min then challenged with sequential addition of 40 and 80 mM KCl to assess 
viability. In experiments with denuded vessels, successful removal of the endothelium was 
verified by contracting with 30 nM of the thromboxane A2 analogue, U46619 and adding 10 
µM acetylcholine. Lack of relaxation in response to acetylcholine indicated no endothelium 
was present. 
To assess the effects of increasing concentrations of sphingosine, S1P and AEA on aortic 
vascular tone, vessels were pre-contracted with 30 nM U46619. A dose-response curve was 
generated by the cumulative addition of AEA (1 nM to 100µM), sphingosine and S1P (1 nM 
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to 5 µM) in half-log molar concentrations. In some experiments, the effect of the dual SK1/2 
inhibitor SKi, on agonist-induced relaxation was investigated. In these experiments, 10 µM 
SKi was added 5 min prior to the addition of U46619 and was present throughout the 
generation of the dose-response curve. To investigate the receptor subtypes responsible for 
the S1P-mediated vasodilatation in the mouse aorta, rings were pre-incubated for 10 min with 
either 10 µM W146 or 10 µM of the combined S1P1/3 antagonist, 2-amino-N-(3-octylphenyl)-
3-(phosphonooxy)-propanamide (VPC 23019, Tocris Bioscience, Bristol, U.K. (Davis et al., 
2005)). Inhibitors remained in the bath for the duration of the experiment. For all 
experiments, sphingosine and S1P were prepared and diluted in a 4 mg/ml aqueous solution 
of bovine serum albumin (BSA) and stored on ice (Rosen et al., 2009). 
 
2.5 Immunohistochemistry 
For analysis of S1P1 expression and location, aortae from vehicle- and W146-treated mice 
were carefully excised following cervical dislocation. The aortae were cleared of any 
surrounding fat and connective tissue and fixed in 10% formalin at 4 ˚C for 24 h. Following 
fixation, the aortae were dehydrated, paraffin-embedded and sectioned on a rotary microtome 
at 5 µm. Slides were subjected to a standard immunohistochemical protocol to study S1P1 
expression (Cuevas et al., 1994). Briefly, antigens were retrieved by microwave pressure 
cooking in citric acid followed by blocking of endogenous peroxidase and non-specific 
binding. Primary antibody against S1P1 was then incubated overnight at 4 ˚C (1:150 dilution 
in 1% (w/v) BSA in PBS, Abcam, Cambridge, U.K.). A peroxidase-labelled DAB method 
followed by counterstaining using haematoxylin was used to visualise the location of S1P1 on 
the aortae. 
 
2.6 Statistical analysis 
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Data are expressed as mean ± S.E.M. where n is the number of different animals or number 
of aortae from individual animals. All statistical analyses were performed using GraphPad 
Prism 5.0 (La Jolla, CA, U.S.A.). Differences in baseline mean arterial blood pressure (MAP) 
were analysed by either unpaired t test or one-way ANOVA with Dunnett’s post hoc test. The 
percentage change in MAP and HR in response to anandamide ± SK inhibitors or S1P 
receptor antagonists were analysed by two-way ANOVA with Bonferroni’s post-hoc 
analysis. For myography experiments, comparisons of drug incubation on U46619 
contraction were analysed by either unpaired Student’s t test or one-way ANOVA while 
dose-response curves were analysed using two-way ANOVA. P<0.05 was considered 
statistically significant. 
 
3. Results 
3.1 Effects of SK inhibitors 
AEA induced a dose-dependent, transient fall in BP, followed by a short pressor response and 
a longer lasting hypotension (Fig. 1). In all experimental groups, MAP had recovered to a 
level not significantly different from pre-injection levels 5 min after the 1mg/kg dose of AEA 
(Supplementary fig. 1). Thus, the initial dose of AEA is unlikely to have influenced the 
response to the second injection of 10mg/kg AEA. Baseline mean arterial blood pressure 
(MAP) was 92.6 ± 3.0 mmHg in vehicle-treated mice (n = 12) which was not significantly 
different from animals injected with the dual SK1/2 inhibitor, SKi (75 mg/kg) 24 h 
previously (91.6 ± 2.6mmHg; n = 12, Fig, 2A). However, baseline HR was reduced by SKi 
treatment (495.4 ± 22.4 bpm in control; n = 12 versus 421.3 ± 22.3 bpm in SKi group; n = 
12). Since baseline blood pressure data were very consistent within experimental groups, 
reductions are reported as % values. In mice treated with SKi, the hypotensive response to 
AEA was inhibited (20.7 ± 3.7% of baseline with vehicle (n = 8) versus 6.7 ± 1.9% of 
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baseline with SKi (n = 7), Fig. 2B). AEA also had a tendency to lower HR during phase I in 
control and SKi-treated animals although this was not significant (455.0 ± 40.8 bpm in 
DMSO-treated animals versus 412.0 ± 28.5 bpm in SKi-treated animals following AEA 
administration; n = 5-8). Methanandamide (10 mg/kg) also caused a rapid phase I 
hypotensive response but this was smaller compared to AEA (9.9 ± 6.6 % of baseline value; 
n=3). Tocrisolve, the AEA vehicle, had no effect on MAP (Fig. 2B) or on HR (data not 
shown). 
 
In order to determine which SK isoform was important in mediating the AEA-induced 
hypotension, these experiments were repeated using SK1- and SK2-selective inhibitors, 
BML-258 (SK1-I) and ROMe, respectively. Neither inhibitor had any effect on baseline HR 
but ROMe and, to a greater extent, BML-258 significantly lowered baseline MAP (Fig. 2C). 
In mice treated with the vehicle, the maximum phase I hypotensive response to AEA was 
16.5 ± 8.2% of baseline MAP at 1 mg/kg (n = 9) and 43.6 ± 7.2% of baseline MAP at 10 
mg/kg (n = 9; Fig. 2D). In mice pretreated with BML-258, the hypotension induced by AEA 
was abolished and instead a small increase in MAP was observed (6.8 ± 3.6% at 1 mg/kg (n = 
5) and 4.8 ± 7.8% at 10 mg/kg (n = 5)). Conversely, ROMe had no significant effect on the 
hypotension induced by AEA (Fig. 2D). As found previously, AEA caused some transient 
bradycardia but there were no significant differences in the magnitude of the bradycardia 
across the groups at either dose of AEA (Supplementary fig. 2). Tocrisolve treatment had no 
effect on either MAP or HR in either vehicle-, BML-258- or ROMe-pretreated animals. 
 
3.2 Effect of an S1P1 antagonist 
Our data suggest that injection of AEA causes the generation of S1P catalysed by SK1 which 
is responsible for the phase I hypotensive effect. We therefore hypothesised that the vascular 
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component of the hypotensive response may be mediated via activation of S1P1 on the 
vasculature. To test this, we pretreated mice with the selective S1P1 antagonist W146 (10 
mg/kg) for 30 min before recording the responses to AEA. W146 treatment did not 
significantly affect baseline MAP (Fig. 3A) but attenuated the hypotensive response to 10 
mg/kg AEA (Fig. 3B). Tocrisolve had no effect on MAP or HR in either the vehicle- or 
W146-treated mice (data not shown). Interestingly, when systolic and diastolic pressure 
changes were analysed, it could be seen that W146 completely attenuated the fall in systolic 
pressure induced by 10 mg/kg AEA (-15.7 ± 2.5 mmHg in vehicle-treated mice (n = 8) versus 
0.04 ± 2.3 mmHg in W146-treated mice (n = 8); Fig. 3C) but had no effect on the diastolic 
pressure (data not shown). Thus, mice treated with W146 experience a significant increase in 
pulse pressure following 10 mg/kg AEA injection (36.6 ± 6.3 mmHg with vehicle (n = 5) 
versus 55.0 ± 2.2 mmHg with W146 (n = 5)). Again, AEA-induced a bradycardic effect 
which was not significantly different in W146 versus vehicle-treated mice (data not shown). 
 
3.3 Vasodilation to S1P in isolated mouse aortae 
In denuded, pre-contracted mouse aortic rings, addition of sphingosine or S1P (1 nM to 5 
µM) prepared in 4 mg/ml BSA solution (Rosen et al., 2009) induced a dose-dependent 
relaxation (Fig. 4). SKi had no significant effect on the pre-contraction to U46619 (Fig. 4A). 
In vessels incubated with SKi prior to pre-contraction with U46619, the relaxation to 
sphingosine was markedly attenuated (maximum relaxation of 11.4 ± 4.4% with SKi, n = 3 
versus 25.2 ± 8.0% with vehicle, n = 9, Fig. 4B). In endothelium intact, pre-contracted rings, 
addition of S1P did not induce any relaxation (n=5; data not shown) and sphingosine only 
induced a very small relaxation (maximum of 6.8 ± 2.8%; n=6) which was not sensitive to 
SKi (maximum relaxation 7.6 ± 2.9%; n=5). Similarly, AEA only induced a small relaxation 
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at a concentration of 100µM (5.9 ± 4.8% (n=5) and produced no relaxation in denuded rings 
(n=5; data not shown). 
In order to determine which S1P receptors on the vasculature are important in the S1P-
mediated vasodilation in denuded mouse aortae, vessels were pretreated with either W146 (a 
S1P1 antagonist) or VPC 23019 (a S1P1/3 antagonist). Neither W146 nor VPC 23019 affected 
the preconstriction of the aorta in response to U46619 (Fig. 4C). S1P induced a maximum 
relaxation of 32.7 ± 5.6% (Fig. 4D) which was almost completely abolished by W146 
(maximum relaxation reduced to 6.5 ± 3.1%; n = 8) or VPC 23019 (maximum relaxation was 
reduced to -1.0 ± 7.6%; n = 5). This suggests that S1P1 is the receptor subtype responsible for 
the vasodilator effect of S1P at the level of vascular smooth muscle cells (VSMCs). To 
exclude the possibility that VPC23019 and W146 were inhibiting relaxation to S1P by acting 
as direct BKCa inhibitors, relaxation to the BKCa activator NS1619 was studied. In 
endothelium-intact rings, NS1619 induced a relaxation at 30µM which was unaffected by 
pretreatment with either 10µM VPC 23019 or 10µM W146 (Fig. 4E). 
 
3.4 Distribution of S1P1 on the mouse aorta 
In human tissue, although S1P1 is abundantly expressed on cardiomyocytes and endothelial 
cells of coronary vessels, it was not found on the aortic smooth muscle, where S1P2 and S1P3 
were expressed (Mazurais et al., 2002). Since our data suggest that S1P1 is responsible for 
S1P-mediated dilation in denuded mouse aortae, we examined S1P1 expression on the smooth 
muscle and endothelium by immunohistochemistry. Expression of S1P1 was found 
throughout the media of the vessels with strong immunostaining in the endothelium. 
Pretreatment of the mice with W146 did not affect receptor expression pattern or density 
(Fig. 5). 
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4. Discussion 
In this study, we have described a novel mechanism which underlies the phase I hypotensive 
response to the endocannabinoid AEA in the anaesthetised mouse. The response appears to 
be dependent on SK1 activity but not SK2 activity, and at least part of the hypotensive 
response is via activation of S1P1, presumably through generation and release of S1P. The in 
vitro data indicate that while S1P has a vasodilator effect via activation of S1P1, this is at the 
level of the medial smooth muscle rather than the endothelium. Thus, the AEA-induced 
activation of SK and generation of S1P may occur within resistance vessels but does not 
occur within conduit vessels such as the aorta. 
 
4.1 Effect of SK inhibition on basal MAP 
Both BML-258 and ROMe induced a lowering of basal MAP when injected 24 h before 
measurement. This was particularly marked with the selective SK1 inhibitor BML-258, 
where the reduction was around 40%. This is in contrast to SK1 knockout mice which present 
with no change in MAP (Olivera et al., 2010), although this may be due to some 
compensatory mechanism. Similarly, SKi had no effect on MAP despite lowering basal HR 
and this may represent an off-target effect of SKi, The lowering of basal MAP strongly 
suggests that the SK1/S1P-axis participates in the physiological regulation of BP. However, 
since W146 did not induce any change in basal MAP, it seems that either S1P1 is not 
involved in maintenance of basal MAP or other S1P receptor subtypes can be activated to 
maintain BP when S1P1 is blocked. Other studies (Spijkers et al., 2012) have similarly 
observed a BP reduction in normotensive rats treated with FTY720 or N-N-
dimethylsphingosine, both of which are SK1 inhibitors (Tonelli et al., 2010). The reduction in 
basal MAP could be due to effects on TPR or cardiac output (CO) or a combination of both. 
Basal HR was unchanged by SK inhibition but negative inotropic effects could account for a 
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lowering of CO. However, most studies have claimed that S1P has negative inotropic and 
chronotropic effects (Landeen et al., 2008; Means et al., 2008); therefore, blocking generation 
of S1P in vivo would be expected to raise CO rather than lowering it. A reduction in TPR in 
response to blockade of SK is more likely. Indeed, several studies have indicated that an 
action of S1P on S1P2 can cause vasoconstriction of resistance vessels (Bischoff et al., 2000b; 
Bischoff et al., 2000a) and mice lacking S1P2 exhibit an overall reduction in vascular tone 
and contractile responsiveness (Lorenz et al., 2007). Expression of dominant negative SK1 in 
VSMCs and resistance arteries decreases vascular tone and myogenic responsiveness (Bolz et 
al., 2003), all of which could result in a lowering of basal MAP. 
 
4.2 SK in anandamide-induced hypotension 
Both 1 and 10 mg/kg AEA dose-dependently induced a rapid fall in MAP and HR which was 
of a similar magnitude to that reported previously (Lake et al., 1997; Malinowska et al., 
2001). In a small number of experiments the stable anandamide analogue methanandamide 
also produced a rapid fall in MAP although this was of a smaller magnitude, suggesting that 
arachidonic acid metabolites of AEA may play some part in the phase I hypotensive 
response. Here, we focussed on the phase I hypotensive response to AEA and found it to be 
dependent on SK1 but not SK2 activity. Indeed, previous studies have noted that 
cannabinoids can modulate sphingolipid metabolism (Galve-Roperh et al., 2000; Gustafsson 
et al., 2009; Mair et al., 2010). Moreover, SK1 has been shown to be involved in a number of 
agonist-induced responses involving S1P generation that subsequently acts via so called 
‘inside-out’ signalling (Takabe et al., 2008). 
It is possible that AEA employs a signalling pathway that induces phosphorylation and 
activation of SK1 via extracellular signal-regulated kinases-1/2, and we previously 
demonstrated this effect in isolated rat coronary arteries in vitro (Mair et al., 2010). Our data 
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do not rule out activation of TRPV1 in response to injection of AEA. Indeed, generation of 
S1P via SK1 may activate TRPV1 to produce bradycardia and also activate S1P1 on vessels 
to produce vasodilation- both of which would contribute to the phase I hypotension. In 
support of this, the bradycardic effect in response to 10mg/kg AEA tended to be lower in 
animals treated with BML-258 (Supplementary fig. 2) and a recent study has claimed that 
S1P can sensitise TRPV1 channels on sensory neurons to stimuli (Langeslag et al., 2014). 
Activation of CB2 receptors by AEA may also be involved, based on our own data in the rat 
(Mair et al., 2010) and an in vivo study where injection of the CB2 receptor agonist HU-308 
induced hypotension (Hanus et al., 1999). An indirect effect of SK1 is also a possibility since 
sphingosine can act as a CB1 antagonist and may blunt the AEA response in animals 
pretreated with an SK1 inhibitor, where sphingosine is likely to accumulate (Paugh et al., 
2006). In the mouse aorta, our in vitro data indicate that conversion of sphingosine to S1P is 
required for vasodilatation to occur and that sphingosine itself does not mediate a vasodilator 
effect. Blocking this conversion in vivo using BML-258 or SKi would prevent the vasodilator 
actions of endogenous S1P. Interestingly, the presence of the endothelium prevented 
relaxation to S1P albeit that this was in a conduit vessel. Further experiments are required to 
assess the vasodilator effects of S1P in an endothelium-intact resistance vessel which would 
be more relevant to modulating total peripheral resistance. 
 
4.3 Effect of S1P1 antagonist on the response to anandamide 
The S1P1 antagonist W146, at a dose used in previous studies (Oo et al., 2011; Tarrason et 
al., 2011), had a tendency to inhibit the hypotensive response to AEA. However, what was 
striking was the effect of W146 pretreatment on the change in systolic BP in response to 
AEA injection. The fall in systolic BP was inhibited by W146 but the fall in diastolic BP in 
response to AEA was preserved. This will lead to a rise in pulse pressure which is determined 
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by a number of factors including the stroke volume of the heart, compliance of the aorta and 
the resistance to flow in the arterial tree. S1P1 is the predominant isoform expressed on 
cardiac myocytes (Means et al., 2009) and activation causes a negative inotropic effect via Gi 
and decreased cAMP within the cardiomyocytes. Consequently, blocking S1P1 may lead to 
an increase in the force of contraction of the heart and an increased pulse pressure following 
AEA administration. What causes this effect remains to be determined but it is unlikely to be 
via an action of AEA at CB receptors since these are Gi linked and would therefore mediate 
negative inotropy and chronotropy. In the absence of W146, S1P generated by injection of 
AEA may blunt the reflex rise in stroke volume, leading to a fall in measured systolic BP. 
However, W146 may also affect vascular compliance which would increase the pulse 
pressure and, as we have demonstrated in vitro where preincubating aortic rings with W146 
almost completely blocked the relaxation in response to S1P. Thus if AEA is causing 
hypotension through generation of S1P, then inhibition of S1P1 in the aorta (and perhaps also 
resistance arterioles) may ultimately lead to decreased relaxation and an increase in pulse 
pressure.  
 
4.4 Vascular actions of sphingosine and S1P 
In this study, S1P and sphingosine both elicited a modest vasodilator response in denuded 
mouse aortic rings. However, very little relaxation was observed in aortic rings with intact 
endothelium which is in contrast to the results presented by others (Roviezzo et al., 2014). To 
our knowledge, this is the first study to characterise the vascular actions of sphingosine in 
mouse aorta. Our results agree with the effects in porcine aorta (Hsiao et al., 2005) and 
coronary arteries (Murohara et al., 1996) but are in contrast to studies reported in rat aortae 
and mesenteric arteries where there was no effect, and in rat renal arteries where there was a 
vasoconstriction (Johns et al., 1999; Bischoff et al., 2000b). Sphingosine may inhibit Ca
2+
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flux from the sarcoplasmic reticulum and L-type Ca
2+
 channels as observed in 
cardiomyocytes (McDonough et al., 1994) or it may inhibit protein kinase C, which is 
activated by U46619 and has contraction-promoting effects (Studer et al., 1994). However, 
since we found that the dual SK1/2 inhibitor, SKi prevented the relaxation to sphingosine, we 
conclude that metabolism of sphingosine to S1P and a direct relaxation of VSMCs is the 
likely mechanism in denuded mouse aortae. S1P is generally reported to constrict denuded 
vessels (Bischoff et al., 2000b) and to dilate only endothelium-intact mouse and rat thoracic 
aorta (Nofer et al., 2004; Roviezzo et al., 2006). However, we found S1P to relax denuded 
aortic rings and this was of a similar magnitude to what we observed in denuded rat coronary 
artery (Mair et al., 2010). 
VSMC abundantly express S1P2 and S1P3 (Means et al., 2009), both of which have been 
linked to increases in intracellular Ca
2+
 and vasoconstriction, making it unlikely that S1P 
induces relaxation through these receptors. We speculated that S1P1 may be the receptor 
responsible for S1P-mediated vasodilation. Preincubation of vessels with W146 significantly 
inhibited the relaxation to S1P, suggesting that S1P1 is indeed the main subtype responsible 
for S1P-induced vasodilation in this vessel. Use of the combined S1P1/3 antagonist did not 
have a significantly greater effect than W146, suggesting that S1P3 did not contribute 
significantly to the response in the mouse aorta. Curiously, in endothelium-intact vessels, the 
vasodilator response to S1P was not seen, despite S1P1 being detected 
immunohistochemically on the endothelium. It is possible that in a conduit vessel, such as the 
aorta, the endothelial S1P1 receptors are less sensitive or that another S1P receptor subtype 
opposes the vasodilation mediated via activation of S1P1 in the VSMCs. 
Other studies in resistance vessels rather than conduit vessels have also reported expression 
of S1P1 receptors. In the rat, Yin et al (2012), demonstrated expression in cardiac 
microvasculature while a study by Hemmings et al (2004) used Western blotting of 
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homogenised mesentery and showed expression of S1P1 receptor which was decreased in 
aged rats. In human mesenteric and skeletal muscle resistance vessels, expression of S1P1-3 
receptors was detected (Hui et al., 2015). In that study the authors noted wide variability in 
receptor expression between vascular beds (and between species when they studied 
expression in mouse cremaster skeletal muscle arteries) and so it seems probable that a 
balance exists between dilator and constrictor effects of S1P dependent on receptor 
distribution, abundance and access of S1P to these receptors. 
 
4.5 Conclusions 
In conclusion, this study provides evidence that the SK1/S1P-axis is important not only in 
physiological BP regulation but is necessary for the phase I hypotension in response to AEA. 
Generation of S1P in response to AEA likely activates S1P1 to reduce TPR and lower MAP. 
In conduit vessels, this is at the level of the VSMCs while in resistance vessels, an effect of 
S1P receptors on the endothelium may also contribute, although this remains to be 
determined. These findings have important implications in our understanding of the 
hypotensive and cardioprotective actions of cannabinoids and may aid the identification of 
novel pharmacological targets for the treatment of hypertension. 
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Figure legends 
Fig. 1: Representative experimental recording showing the changes in BP induced by i.v. 
injection of two doses of anandamide (1 and 10 mg/kg) in mice. Arrows indicate the 
injections of anandamide which were administered at 5 min intervals. 
 
Fig. 2: Effect of pretreatment with SK inhibitors on the peak hypotensive response to i.v. 
anandamide administration. (A) Mice were pre-treated with either vehicle or dual SK1/2 
inhibitor, SKi (75 mg/kg) for 24 h prior to baseline MAP measurement. n = 12. (B) Baseline 
values were compared to the peak hypotensive response following tocrisolve or anandamide 
injection. **P<0.01, n = 4-8, two-way ANOVA. (C) Mice were pre-treated with either 
vehicle or the selective SK1 or SK2 inhibitors (75 mg/kg), BML-258 or ROMe respectively, 
for 24 h prior to baseline MAP measurement. *P<0.05 and ***P<0.001, n = 5-12, one-way 
ANOVA. (D) Baseline values were compared to the peak hypotensive response following 
increasing doses of anandamide. *P<0.05, n = 5-9, two-way ANOVA. 
 
Fig. 3: Effect of the S1P1 antagonist W146 on the peak hypotensive response to i.v. 
administration of anandamide. (A) Mice were pre-treated with either vehicle or W146 (10 
mg/kg) for 30 min prior to baseline MAP measurements. n = 6-12. (B and C) Baseline MAP 
and systolic BP values were compared to the peak hypotensive response following increasing 
doses of anandamide. *P<0.05 and ***P<0.001, n = 5-6, two-way ANOVA. 
 
Fig. 4: Responses to sphingosine and S1P in the presence and absence of a SK inhibitor and 
S1P receptor antagonists in denuded mouse aortic rings. (A) Vessels were pre-treated with 
the dual SK1/2 inhibitor SKi prior to U46619-induced contraction. n = 3-9. (B) Dose-
response to sphingosine and in the presence of SKi (10 μM) were produced. *P<0.05 versus 
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sphingosine alone, n = 3-9, two-way ANOVA. (C) Vessels were pre-treated with selective 
S1P1 antagonist W146 or the S1P1/3 antagonist, VPC 23019 (both 10 μM) prior to U46619-
induced contraction. n = 5-9. (D) Dose-response to S1P in the presence and absence of W146 
and VPC 23019 were produced. (E) The BKCa channel opener NS1619 produced a 
vasodilation in endothelium-intact aortic rings which was not affected by either W146 or 
VPC 23019. ***P<0.001 versus S1P alone, n = 5-9, two-way ANOVA. 
 
Fig. 5: S1P1 immunostaining in the endothelium and medial vascular smooth muscle cells of 
aortae from vehicle- and W146-treated mice. Representative photomicrographs (n=6) of 
sections stained with S1P1 and counterstained with haematoxylin. Specific staining is seen as 
a brown colour and was visualised via a peroxidase-DAB method (magnification x 400 for all 
panels). 
 
Supplementary Fig. 1: Recovery time of MAP following injection of AEA. Mice were pre-
treated with either DMSO (control; n=9), BML-258 (n=5) or ROMe (n=4) 24h prior to the 
i.v. injection of AEA or Tocrisolve (solvent; n=6). AEA was injected at increasing doses of 1 
and 10mg/kg at 5min intervals. To assess the duration of the phase 3 response induced by 
AEA and the time taken to return to baseline, MAP was analysed 5min after the injection of 
the relevant dose and expressed as percentage of baseline MAP. In all groups, MAP had 
recovered to baseline levels 5 min after injection of the lower dose of AEA. Data are 
expressed as mean± S.E.M. *P<0.05 vs. control.  
 
Supplementary Fig. 2: Variable bradycardic response during phase 1 hypotension. Mice were 
pre-treated with either DMSO, (control) BML-258 or ROMe (both 75 mg/kg) and 
anaesthetised with isoflurane. The %-decrease from pre-injection values for HR during the 
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initial hypotension in response to 1 and 10 mg/mL AEA or the equivalent amount of 
tocrisolve solvent was quantified for the different treatment groups. Data are expressed as 
mean ± S.E.M. Numbers in the bars denote n-numbers. P=ns for comparisons made with the 
control group. 
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